Niagen Bioscience, Inc. NAGE R2KR3KPHARMA
Company Overview
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Why Investors Should Care
Generates a return on equity of 21.8%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 18.8%.
Revenue has grown at a 20.8% CAGR over the past five years.
Trades at a P/E of 16.7, below the sector median of 25.2.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $129.42M (+29.9% YoY); net profit $17.38M.
- Trailing 12 Months Year-on-year growth — revenue -4.3%, earnings -75.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.84% |
| 1 Year: | -4.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -75.00% |
Stock Price Performance
| 1 Year: | -68.68% |
| 6 Months: | -37.35% |
| 3 Months: | -8.12% |
| 1 Month: | +4.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.39 · Neutral
P/E of 16.68 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 21.8%.
- Compounding revenue at 20.8% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 69.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NAGE Niagen Bioscience, Inc. R2KR3KPHARMA | 3.17 | 16.68 | $252.47M | 0.00% | 18.82% | 21.80% | 20.84% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Jan 2015 | Apr 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 4.22M | 6.08M | - | 6.57M | 7.80M | 8.12M | 10.05M | 11.10M | 12.05M | 14.35M | 15.29M | 14.18M | 14.68M | 17.70M | 17.31M | 17.26M | 16.73M | 17.06M | 22.56M | 20.32M | 19.50M | 22.15M | 22.74M | 25.58M | 30.48M | 31.12M | 33.99M | 31.47M | 29.79M |
| Gross Profit | 1.52M | 1.42M | 1.93M | 2.47M | 2.48M | 1.60M | 2.84M | 3.67M | 1.86M | 2.01M | 1.62M | 2.11M | 2.92M | 3.83M | 3.14M | 3.85M | 4.36M | 5.30M | 6.25M | 6.75M | 8.31M | 9.09M | 8.45M | 9.23M | 10.81M | 10.58M | 10.53M | 10.04M | 10.21M | 13.52M | 12.36M | 11.97M | 13.46M | 13.69M | 16.24M | 19.33M | 20.23M | 21.93M | 19.98M | 19.31M |
| Operating Income | -647.43K | -1.10M | -906.08K | -184.06K | 177.13K | -1.24M | 32.07K | 158.81K | -924.16K | -2.17M | -1.77M | -2.65M | -3.18M | -8.78M | -8.40M | -7.94M | -8.60M | -8.37M | -7.18M | -6.89M | -5.89M | -3.69M | -4.20M | -7.36M | -5.55M | -8.84M | -7.73M | -6.39M | -3.06M | -1.97M | -2.32M | -1.15M | -731.00K | -256.00K | 1.60M | 4.77M | 3.19M | 4.24M | 1.58M | 700.00K |
| Net Income | -659.65K | -1.23M | -1.03M | -315.19K | -3.72K | -1.43M | 255.62K | -82.67K | -954.39K | -2.15M | -1.93M | -2.76M | 2.14M | -8.82M | -8.44M | -8.05M | -8.61M | -8.34M | -7.75M | -7.20M | -5.90M | -3.71M | -4.21M | -7.38M | -5.57M | -8.86M | -7.74M | -6.40M | -985.00K | -1.90M | -2.19M | -959.00K | -492.00K | -15.00K | 1.88M | 5.06M | 3.61M | 4.58M | 6.32M | 963.00K |
| Diluted EPS | - | - | -0.03 | -0.01 | - | - | 0.01 | 0.00 | -0.03 | -0.06 | -0.05 | -0.07 | 0.04 | -0.17 | - | - | -0.16 | - | - | - | - | -0.06 | -0.07 | -0.12 | -0.08 | -0.13 | -0.11 | -0.09 | -0.01 | -0.03 | -0.03 | -0.01 | -0.01 | 0.00 | 0.02 | 0.06 | 0.04 | 0.05 | 0.07 | 0.01 |
| R&D Expense | - | - | 121.09K | 175.41K | 188.69K | - | 464.07K | 751.73K | 772.80K | - | 664.00K | 850.00K | 1.04M | - | 1.44M | 1.41M | 1.35M | 1.17M | 1.07M | 1.04M | 919.00K | 895.00K | 841.00K | 787.00K | 1.00M | 996.00K | 1.08M | 1.25M | 1.22M | 1.19M | 1.36M | 1.24M | 2.10M | 1.32M | 1.29M | 1.26M | 1.57M | 1.79M | 1.48M | 1.51M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.57M | 8.11M | 11.61M | 10.16M | 15.31M | 17.88M | 21.66M | 21.20M | 31.56M | 46.29M | 59.26M | 67.45M | 72.05M | 83.57M | 99.60M | 129.42M |
| Gross Profit | 2.94M | 2.47M | 2.28M | 3.13M | 5.33M | 7.53M | 10.39M | 10.48M | 16.05M | 25.77M | 35.27M | 41.49M | 42.80M | 50.78M | 61.59M | 83.19M |
| Operating Income | -2.02M | -7.86M | -11.64M | -4.39M | -5.23M | -2.07M | -2.91M | -16.38M | -33.17M | -31.30M | -19.85M | -27.07M | -18.63M | -5.60M | 7.73M | 16.28M |
| Net Income | -2.05M | -7.89M | -11.66M | -4.42M | -5.39M | -2.77M | -2.93M | -11.38M | -33.32M | -32.15M | -19.93M | -27.13M | -16.54M | -4.94M | 8.55M | 17.38M |
| Diluted EPS | -0.04 | -0.12 | - | - | - | - | - | - | - | - | -0.33 | -0.40 | -0.24 | -0.07 | 0.11 | 0.20 |
| R&D Expense | - | 96.79K | 142.00K | 134.04K | 513.67K | 891.60K | 2.52M | 4.01M | 5.48M | 4.42M | 3.42M | 3.83M | 4.83M | 4.96M | 6.02M | 6.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.51M | 6.27M | 9.03M | 8.99M | 11.52M | 18.75M | 19.75M | 62.72M | 42.23M | 40.25M | 38.36M | 57.84M | 54.06M | 54.96M | 68.28M | 106.41M |
| Total Equity | 1.05M | 4.94M | 2.56M | 3.99M | 5.67M | 4.00M | 5.27M | 9.97M | 53.83M | 27.18M | 20.45M | 16.42M | 31.73M | 28.67M | 28.46M | 46.09M | 76.53M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | 18.81M | 16.70M | 28.22M | 20.30M | 27.20M | 44.50M | - |
| Long Term Debt | - | - | - | - | - | 1.98M | 3.35M | 0 | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | 5.04M | 3.32M | 7.52M | 13.47M | 9.78M | 8.89M | 15.05M | 19.80M | 21.93M | 26.11M | 25.39M | 26.51M | 22.18M | 29.87M |
| Current Liabilities | - | 1.14M | 3.34M | 4.76M | 2.84M | 4.98M | 9.59M | 8.87M | 8.09M | 14.44M | 15.06M | 16.48M | 17.61M | 17.87M | 20.62M | 17.95M | 19.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.66M | -4.10M | -10.12M | -3.91M | -2.58M | -2.11M | -2.94M | -9.80M | -20.91M | -20.44M | -10.60M | -24.16M | -15.10M | 7.12M | 12.11M | 13.50M |
| Investing Cash Flow | -199.14K | -176.66K | -76.56K | 998.65K | 1.59M | -647.73K | -1.72M | 4.60M | -1.77M | -249.00K | -165.00K | -409.00K | -334.00K | -143.00K | -143.00K | -292.00K |
| Financing Cash Flow | 4.62M | 2.47M | 10.30M | 4.65M | 2.69M | 4.34M | 754.27K | 48.95M | -90.00K | 16.88M | 8.65M | 36.09M | 7.65M | -90.00K | 5.37M | 6.92M |
| Capital Expenditure | -169.14K | -150.66K | -24.55K | -137.35K | -123.10K | -525.23K | -1.50M | -1.17M | -1.32M | -743.00K | - | - | - | - | - | - |
| Free Cash Flow | -2.83M | -4.25M | -10.14M | -4.04M | -2.70M | -2.64M | -4.44M | -10.97M | -22.23M | -21.18M | - | - | - | - | - | - |
| Share Buybacks | - | - | -8.20K | - | - | - | - | 0 | 404.00K | - | - | - | - | - | 0 | 251.00K |
Ratios (Annual)
Figures in %.
| Metric | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 38.9% | 30.5% | 19.6% | 30.8% | 34.8% | 42.1% | 48.0% | 49.4% | 50.9% | 55.7% | 59.5% | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating Margin % | -26.7% | -96.9% | -100.2% | -43.2% | -34.2% | -11.6% | -13.4% | -77.2% | -105.1% | -67.6% | -33.5% | -40.1% | -25.9% | -6.7% | 7.8% | 12.6% |
| Net Margin % | -27.1% | -97.3% | -100.4% | -43.5% | -35.2% | -15.5% | -13.5% | -53.7% | -105.6% | -69.4% | -33.6% | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% |
| ROE % | -41.6% | -308.2% | -292.0% | -78.0% | -134.8% | -52.5% | -29.4% | -21.1% | -122.6% | -157.2% | -121.3% | -85.5% | -57.7% | -17.4% | 18.5% | 22.7% |
| ROCE % | -37.6% | -268.7% | -272.4% | -71.3% | -80.0% | -22.5% | -26.7% | -30.0% | -119.4% | -124.3% | -90.7% | -67.3% | -51.5% | -16.3% | 15.4% | 18.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.25% | 4.18M | $13.77M |
| 2 | SteelPeak Wealth, LLC | 4.39% | 3.50M | $11.52M |
| 3 | Vanguard Capital Management LLC | 2.70% | 2.15M | $7.06M |
| 4 | Tieton Capital Management, LLC | 2.52% | 2.01M | $6.61M |
| 5 | Qube Research & Technologies Ltd | 2.04% | 1.63M | $5.35M |
| 6 | Geode Capital Management, LLC | 1.86% | 1.48M | $4.86M |
| 7 | UBS Group AG | 1.61% | 1.28M | $4.22M |
| 8 | Goldman Sachs Group Inc | 1.59% | 1.26M | $4.15M |
| 9 | Arrowstreet Capital, Limited Partnership | 1.47% | 1.17M | $3.85M |
| 10 | Vanguard Portfolio Management LLC | 1.46% | 1.17M | $3.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NAGE
A longevity conference will offer Niagen samples in Switzerland - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQQWljeVlFbjBJSkJiZkZVTlEwN2N5UjVTR2lCRlpyeTIteTdWaHRheERCbXFNbFZjWk1POVFwRzdya042THZWOUdMS29kaWgtY3BiUlJZOGw2WVc5VlBHcEUwbnNrRHZxMVN4NXN1bzhOcUhnWEZIZGZ5M1RuaWJIaDM1UWNncng2dHc4N1…
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQLVFZMkZkNVgwcmhXNXJkZFBzcDZOWVpKQ2pveTRabDJSX1Z5MWpFTzRYaFlISXJ6QjZVTWpUTi14OVYycVdGY3F0a2loUmctZTZwM2NKX0lsMDBjeFptenV5Nm4wQjVGckFPNlFLdGhWdk1aZkY3bmpQRjBfcS1xbWtYQ3ljRUcyejNVem…
NAGE Price History for Niagen Bioscience Stock - Barchart.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5HalNWUy1raFZzLWpudWNLZ0dGTl85MjE3NDVjZExXMm5VNlAwMTRpSldnVVRkcTRGT2FaRmhfWnBPa1V0UnVydWJHei1PNnVXZ2pDZEVRNGFtSTJfelBSUkk1V0ZyRmd0cHdSQTBZbXlvajI2Y1Ew?oc=5" target="_blank">NAGE Pr…
Niagen Bioscience, Inc. (NASDAQ: NAGE) Share Price, NAGE Stock News, NAGE Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9FOFB3c21Na3hWQUZEaEVkZEt4WTdmWEp3SkVyOHRMMWl3dnAyQndYdV83cXdGa0FhS29sUkZseHphbE1DNUZMRGk5Y1F0Y3VVVHJ6UjJR?oc=5" target="_blank">Niagen Bioscience, Inc. (NASDAQ: NAGE) Share Price,…
$NAGE stock is down 19% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRXdCandCb0pWNDc0M18zRGJOM0JHX2dMYjBQczN3VF9UV0pOVHpGQVNSblI2cDY4RkZZMmRaTGNFdWlrT3ctbndZRE5MRXJqUlVZX3gwVDkycFFHMmUzYXExcHFmTm1TM1V0R2Z4X0tTX2NWNHE3ZnVGQmtSVXhRZkxOei00RkNHVW9PTk…
Niagen Bioscience (NAGE) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNX0t6R1Zac0JERkpyRTNQa1ZLcU92T2tIRjZvVENVSEVHQ2ZmWW1HRjVXR3VxZW01ZjlxVlQ3UW1VdjBpU284MFdqcHl1ZXI1UkJEV0pjOUVOUUtOdW1KbW43LXo2RTFVNnFfNTZScXhrYjJqNFBLZDVveHBKS1lzYU45ekNvbHJTMkFSel…
NAGE — Frequently Asked Questions
What is the current share price of Niagen Bioscience, Inc. (NAGE)?
As of 2026-09-07 16:24 PDT, Niagen Bioscience, Inc. (NAGE) trades at $3.17 on NasdaqCM. Its 52-week range is $2.96 to $10.24.
What is the market capitalisation of NAGE?
Niagen Bioscience, Inc. (NAGE) has a market capitalisation of $252.47M on NasdaqCM.
What is the P/E ratio of NAGE?
NAGE trades at a trailing price-to-earnings (P/E) ratio of 16.68. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.98.
What is the return on equity (ROE) of NAGE?
NAGE has a return on equity (ROE) of 21.80%. Its return on capital employed (ROCE) is 18.82%.
Is NAGE a good stock to buy?
This page provides a data-driven analysis of Niagen Bioscience, Inc. (NAGE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.